Lamivudine resistance and other mutations in the polymerase and surface antigen genes of hepatitis B virus associated with a fatal hepatic failure case

Journal of Gastroenterology and Hepatology (Australia)

Volumn 23, Issue 1, 2008, Pages 67-72

  Bottecchia, Marcelle ^a   Ikuta, Nilo ^b   Niel, Christian ^a   Araujo, Natalia M ^a   Ó, Kycia M R ^a,c   Gomes, Selma A ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b UNIVERSIDADE LUTERANA DO BRASIL   (Brazil)

^c Municipal Health Foundation of Petrópolis   (Brazil)

Author keywords

Hepatitis B virus; Lamivudine; Mutations; Polymerase; Surface antigen

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DNA DIRECTED DNA POLYMERASE; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; MEMBRANE ANTIGEN; VIRUS ANTIGEN; VIRUS DNA;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CASE REPORT; CAUSE OF DEATH; DRUG FATALITY; GENE MUTATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER FAILURE; MALE; MUTAGENESIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; STRUCTURAL GENE; TREATMENT OUTCOME;

EID: 37249001826     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2007.05238.x     Document Type: Article

References (34)

1. Schaefer S. Hepatitis B virus: significance of genotypes. J. Viral Hepat. 2005 12 : 111 24.
2. Bowyer SM, van Staden L, Kew MC, Sim JG. A unique segment of the hepatitis B virus group A genotype identified in isolates from South Africa. J. Gen. Virol. 1997 78 : 1719 29.
3. Kimbi GC, Kramvis A, Kew MC. Distinctive sequence characteristics of subgenotype A1 isolates of hepatitis B virus from South Africa. J. Gen. Virol. 2004 85 : 1211 20.
4. Hasegawa I, Tanaka Y, Kramvis A et al. Novel hepatitis B virus genotype a subtyping assay that distinguishes subtype Aa from Ae and its application in epidemiological studies. J. Virol. 2004 78 : 7575 81.
5. Liaw YF. Management of patients with chronic hepatitis B. J. Gastroenterol. Hepatol. 2002 17 : 406 8.
6. Ben-Ari Z, Daudi N, Klein A et al. Genotypic and phenotypic resistance: longitudinal and sequential analysis of hepatitis B virus polymerase mutations in patients with lamivudine resistance after liver transplantation. Am. J. Gastroenterol. 2003 98 : 151 9.
7. Gauthier J, Bourne EJ, Lutz MW et al. Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine. J. Infect. Dis. 1999 180 : 1757 62.
8. Farrell GC, Teoh NC. Management of chronic hepatitis B virus infection: a new era of disease control. Intern. Med. J. 2006 36 : 100 13.
9. Lai CL. Therapeutic advances in chronic hepatitis B. J. Gastroenterol. Hepatol. 2004 19 (Suppl. S5 9.
10. Torresi J. The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus. J. Clin. Virol. 2002 25 : 97 106.
11. Yeh CT, Chien RN, Chu CM, Liaw YF. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology 2000 31 : 1318 26.
12. Jardi R, Buti M, Rodriguez-Frias F et al. Rapid detection of lamivudine-resistant hepatitis B virus polymerase gene variants. J. Virol. Methods 1999 83 : 181 7.
13. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999 30 : 567 72.
14. Pallier C, Castera L, Soulier A et al. Dynamics of hepatitis B virus resistance to lamivudine. J. Virol. 2006 80 : 643 53.
15. Durantel D, Brunelle MN, Gros E et al. Resistance of human hepatitis B virus to reverse transcriptase inhibitors: from genotypic to phenotypic testing. J. Clin. Virol. 2005 34 (Suppl. 1 S34 43.
16. Jacobson IM. Therapeutic options for chronic hepatitis B: considerations and controversies. Am. J. Gastroenterol. 2006 101 (Suppl. 1 S13 18.
17. Li D, Gu HX, Zhang SY, Zhong ZH, Zhuang M, Hattori T. YMDD mutations and genotypes of hepatitis B virus in northern China. Jpn. J. Infect. Dis. 2006 59 : 42 5.
18. Akuta N, Suzuki F, Kobayashi M et al. Virological and biochemical relapse after discontinuation of lamivudine monotherapy for chronic hepatitis B in Japan: comparison with breakthrough hepatitis during long-term treatment. Intervirology 2005 48 : 174 82.
19. Lok AS, Zoulim F, Locarnini S et al. Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay. J. Clin. Microbiol. 2002 40 : 3729 34.
20. Pas SD, de Man RA, Fries E, Osterhaus AD, Niesters HG. The dynamics of mutations in the YMDD motif of the hepatitis B virus polymerase gene during and after lamivudine treatment as determined by reverse hybridisation. J. Clin. Virol. 2002 25 : 63 71.
21. Stuyver L, Van Geyt C, De Gendt S et al. Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy. J. Clin. Microbiol. 2000 38 : 702 7.
22. Niel C, Moraes MT, Gaspar AM, Yoshida CF, Gomes SA. Genetic diversity of hepatitis B virus strains isolated in Rio de Janeiro, Brazil. J. Med. Virol. 1994 44 : 180 6.
23. Kumar S, Tamura K, Nei M. MEGA3: integrated software for molecular evolutionary genetics analysis and sequence alignment. Brief. Bioinform. 2004 5 : 150 63.
24. Pas SD, Niesters HG. Detection of HBV DNA using real time analysis. J. Clin. Virol. 2002 25 : 93 4.
25. Giannini E, Botta F, Testa E et al. The 1-year and 3-month prognostic utility of the AST/ALT ratio and model for end-stage liver disease score in patients with viral liver cirrhosis. Am. J. Gastroenterol. 2002 97 : 2855 60.
26. Pohl A, Behling C, Oliver D, Kilani M, Monson P, Hassanein T. Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection. Am. J. Gastroenterol. 2001 96 : 3142 6.
27. Bartholomew MM, Jansen RW, Jeffers LJ et al. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997 349 : 20 2.
28. Cooley L, Ayres A, Bartholomeusz A et al. Prevalence and characterization of lamivudine-resistant hepatitis B virus mutations in HIV-HBV co-infected individuals. AIDS 2003 17 : 1649 57.
29. Melegari M, Scaglioni PP, Wands JR. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 1998 27 : 628 33.
30. Akuta N, Suzuki F, Kobayashi M et al. Virological and biochemical relapse according to YMDD motif mutant type during long-term lamivudine monotherapy. J. Med. Virol. 2003 71 : 504 10.
31. Araujo NM, Mello FC, Yoshida CF, Niel C, Gomes SA. High proportion of subgroup A' (genotype A) among Brazilian isolates of Hepatitis B virus. Arch. Virol. 2004 149 : 1383 95.
32. Ayres A, Bartholomeusz A, Lau G, Lam KC, Lee JY, Locarnini S. Lamivudine and Famciclovir resistant hepatitis B virus associated with fatal hepatic failure. J. Clin. Virol. 2003 27 : 111 16.
33. Wang JH, Lu SN, Lee CM, Lee JF, Chou YP. Fatal hepatic failure after emergence of the hepatitis B virus mutant during lamivudine therapy in a patient with liver cirrhosis. Scand. J. Gastroenterol. 2002 37 : 366 9.
34. Zhang JM, Wang XY, Huang YX et al. Fatal liver failure with the emergence of hepatitis B surface antigen variants with multiple stop mutations after discontinuation of lamivudine therapy. J. Med. Virol. 2006 78 : 324 8.